Tourmaline Bio (NASDAQ:TRML) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Tourmaline Bio (NASDAQ:TRML - Free Report) in a report released on Monday,Benzinga reports. The firm currently has a $50.00 target price on the stock. HC Wainwright also issued estimates for Tourmaline Bio's Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.64) EPS, Q1 2026 earnings at ($0.93) EPS, Q2 2026 earnings at ($0.94) EPS, Q3 2026 earnings at ($0.95) EPS, Q4 2026 earnings at ($0.96) EPS and FY2026 earnings at ($3.79) EPS.

Several other brokerages have also commented on TRML. Wedbush raised their price target on shares of Tourmaline Bio from $42.00 to $43.00 and gave the company an "outperform" rating in a research note on Friday, March 14th. Lifesci Capital initiated coverage on Tourmaline Bio in a research note on Monday, February 24th. They set an "outperform" rating and a $58.00 target price on the stock. Finally, Chardan Capital began coverage on Tourmaline Bio in a research note on Wednesday, April 23rd. They issued a "buy" rating and a $70.00 price target for the company. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $49.33.

Tourmaline Bio Stock Performance

Shares of Tourmaline Bio stock traded up $0.85 on Monday, reaching $15.39. 494,753 shares of the company were exchanged, compared to its average volume of 271,287. The firm has a market cap of $395.29 million, a price-to-earnings ratio of -5.46 and a beta of 2.11. Tourmaline Bio has a 1-year low of $11.56 and a 1-year high of $29.79. The company's 50-day moving average is $15.36 and its two-hundred day moving average is $18.95.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last posted its earnings results on Friday, May 2nd. The company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.91) by $0.02. As a group, sell-side analysts forecast that Tourmaline Bio will post -3.02 earnings per share for the current year.

Hedge Funds Weigh In On Tourmaline Bio

Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Tourmaline Bio by 4.1% during the fourth quarter. Vanguard Group Inc. now owns 1,106,125 shares of the company's stock valued at $22,432,000 after buying an additional 43,652 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new position in shares of Tourmaline Bio during the 4th quarter valued at about $12,168,000. Velan Capital Investment Management LP grew its stake in shares of Tourmaline Bio by 28.0% in the 4th quarter. Velan Capital Investment Management LP now owns 423,795 shares of the company's stock worth $8,595,000 after purchasing an additional 92,605 shares during the last quarter. Pictet Asset Management Holding SA raised its holdings in shares of Tourmaline Bio by 69.9% in the 4th quarter. Pictet Asset Management Holding SA now owns 419,883 shares of the company's stock worth $8,515,000 after purchasing an additional 172,743 shares in the last quarter. Finally, Acuta Capital Partners LLC lifted its stake in Tourmaline Bio by 5.9% during the fourth quarter. Acuta Capital Partners LLC now owns 351,842 shares of the company's stock valued at $7,135,000 after purchasing an additional 19,747 shares during the last quarter. 91.89% of the stock is currently owned by institutional investors and hedge funds.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.